Abstract | PURPOSE OF REVIEW: Several novel therapeutic approaches exist for treatment of patients with myelodysplastic syndrome, with goals to improve quality of life and prolong survival. This review highlights new therapies from the last 18 months. RECENT FINDINGS: SUMMARY:
|
Authors | Arturo Loaiza-Bonilla, Steven D Gore, Hetty E Carraway |
Journal | Current opinion in hematology
(Curr Opin Hematol)
Vol. 17
Issue 2
Pg. 104-9
(Mar 2010)
ISSN: 1531-7048 [Electronic] United States |
PMID | 20178141
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antineoplastic Agents
- Benzoates
- Enzyme Inhibitors
- Hydrazines
- Pyrazoles
- Thalidomide
- Methyltransferases
- Lenalidomide
- eltrombopag
|
Topics |
- Antineoplastic Agents
(therapeutic use)
- Benzoates
(therapeutic use)
- Enzyme Inhibitors
(therapeutic use)
- Humans
- Hydrazines
(therapeutic use)
- Lenalidomide
- Methyltransferases
(antagonists & inhibitors)
- Myelodysplastic Syndromes
(drug therapy, physiopathology)
- Pyrazoles
(therapeutic use)
- Quality of Life
- Thalidomide
(analogs & derivatives, therapeutic use)
- Treatment Outcome
|